60 Degrees Pharmaceuticals (SXTP) Cash from Operations (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Cash from Operations of 2741559.0 for Q1 2026, down 71.63% year-over-year from 9663579.1 in Q1 2025, and down 61.99% quarter-over-quarter from 1692456.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Cash from Operations (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Cash from Operations for 5 consecutive years, with 2741559.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 71.63% year-over-year to 2741559.0; the TTM figure through Mar 2026 stood at 7993215.0 (down 30.93% YoY), while the FY2025 annual figure was 6849022.0, down 21.26% from the prior year.
- Cash from Operations retreated to 2741559.0 in Q1 2026 per SXTP's latest filing, from 1692456.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 63668.0 in Q4 2023 and bottomed at 3753074.0 in Q3 2023.
- Historically, Cash from Operations has averaged 1343641.0 across 5 years, with a median of 1450128.0 in 2025.
- On a YoY basis, Cash from Operations climbed as much as 55.2% in 2024 and fell as far as 2473.06% in 2024.
- 60 Degrees Pharmaceuticals' Cash from Operations stood at 65977.0 in 2022, then climbed by 3.5% to 63668.0 in 2023, then plunged by 2473.06% to 1638217.0 in 2024, then slipped by 3.31% to 1692456.0 in 2025, then sank by 61.99% to 2741559.0 in 2026.
- Business Quant data shows SXTP's Cash from Operations at 2741559.0 in Q1 2026, 1692456.0 in Q4 2025, and 2109072.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.74 Mn |
| Mar 31, 2026 | -2.74 Mn |
| Dec 31, 2025 | -1.69 Mn |
| Dec 31, 2025 | -1.69 Mn |
| Sep 30, 2025 | -2.11 Mn |
| Sep 30, 2025 | -2.11 Mn |
| Jun 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | -1.45 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.60 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | -1.68 Mn |
| Sep 30, 2024 | -1.68 Mn |
| Jun 30, 2024 | -1.19 Mn |
| Jun 30, 2024 | -1.19 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.14 Mn |
| Dec 31, 2023 | -63,668.00 |
| Dec 31, 2023 | -63,668.00 |